a, Protein levels of PAX5 and IKZF1 in haploinsufficient patient-derived pre-B ALL cells and pre-B ALL cells expressing functional PAX5 and IKZF1. b, Number of viable cells and cell viability upon inducible activation of PAX5 in haploinsufficient patient-derived pre-B ALL (PAX5∆) cells. c, To test whether Pax5 functions as metabolic gatekeeper, BCR–ABL1-induced changes in glycolytic activity and capacity (ECAR), glucose uptake, and ATP levels (normalized to cell numbers) were studied in Pax5 wild-type and Pax5 haploinsufficient pre-B cells in the presence or absence of a BCR–ABL1-transgene. Data shown as mean ± s.d. from three independent experiments and assessed by two-tailed t-test (b, left; c) or two-way ANOVA (b, right). For gel source data, see Supplementary Fig. 1.